SG11201901834WA - Micrornas as biomarkers for endometriosis - Google Patents

Micrornas as biomarkers for endometriosis

Info

Publication number
SG11201901834WA
SG11201901834WA SG11201901834WA SG11201901834WA SG11201901834WA SG 11201901834W A SG11201901834W A SG 11201901834WA SG 11201901834W A SG11201901834W A SG 11201901834WA SG 11201901834W A SG11201901834W A SG 11201901834WA SG 11201901834W A SG11201901834W A SG 11201901834WA
Authority
SG
Singapore
Prior art keywords
mir
international
pct
endometriosis
english
Prior art date
Application number
SG11201901834WA
Inventor
Hugh Taylor
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of SG11201901834WA publication Critical patent/SG11201901834WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 100011101 1110 MIN 111110111110111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/044979 Al 08 March 2018 (08.03.2018) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/7105 (2006.01) G01N 33/50 (2006.01) kind of national protection available): AE, AG, AL, AM, C12Q 1/68 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, PCT/US2017/049284 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (22) International Filing Date: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 30 August 2017 (30.08.2017) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/381,130 30 August 2016 (30.08.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Avenue, New Haven, CT 06511 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor: TAYLOR, Hugh; 14 Sport Hill Road, Easton, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CT 06612 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — (74) Agent: SINGH, Pallab et al.; Riverside Law, LLP, Glen- KM, ML, MR, NE, SN, TD, TG). hardie Corporate Center, 1285 Drummers Lane, Suite 202, Wayne, PA 19087 (US). = (54) Title: MICRORNAS AS BIOMARKERS FOR ENDOMETRIOSIS miR-125b-. miR-150-5p miR- miR-145 = = = = miR-143 miR-500a- miR-451a miR-18a miR-675 miR-3613 _ = ce = = _ ,—, t:I ' IN ii- ii- Fold Chang . © Figure 1 00 1 -1 (57) : Disclosed herein are compositions and methods useful for the diagnosis, assessment, and characterization of endometrio- C:::: ) eqi sis in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with endometriosis. C [Continued on next page] WO 2018/044979 Al MIDEDIMOMMIDIREIERNHOIRIEIMOMER Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201901834WA 2016-08-30 2017-08-30 Micrornas as biomarkers for endometriosis SG11201901834WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381130P 2016-08-30 2016-08-30
PCT/US2017/049284 WO2018044979A1 (en) 2016-08-30 2017-08-30 Micrornas as biomarkers for endometriosis

Publications (1)

Publication Number Publication Date
SG11201901834WA true SG11201901834WA (en) 2019-03-28

Family

ID=61301726

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202102509TA SG10202102509TA (en) 2016-08-30 2017-08-30 Micrornas as biomarkers for endometriosis
SG11201901834WA SG11201901834WA (en) 2016-08-30 2017-08-30 Micrornas as biomarkers for endometriosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202102509TA SG10202102509TA (en) 2016-08-30 2017-08-30 Micrornas as biomarkers for endometriosis

Country Status (11)

Country Link
US (3) US10982282B2 (en)
EP (1) EP3506912B1 (en)
JP (2) JP2019528081A (en)
KR (1) KR20190057305A (en)
CN (1) CN109890394A (en)
AU (1) AU2017319325A1 (en)
BR (1) BR112019004075A2 (en)
CA (1) CA3035429A1 (en)
MX (1) MX2019002425A (en)
SG (2) SG10202102509TA (en)
WO (1) WO2018044979A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190057305A (en) 2016-08-30 2019-05-28 예일 유니버시티 MicroRNAs as biomarkers for endometriosis
CA3073829A1 (en) * 2017-08-30 2019-03-07 Dot Laboratories, Inc. Methods and compositions for detecting and treating endometriosis
WO2020014566A2 (en) * 2018-07-13 2020-01-16 Yale University Compositions and methods for treating endometriosis
KR102089559B1 (en) * 2018-08-31 2020-03-16 차의과학대학교 산학협력단 Biomarker for diagnosing or predicting reactivity to FSH of ovary
US11315660B2 (en) 2018-10-31 2022-04-26 Dot Laboratories, Inc. Method of detecting and treating endometriosis in a female subject
US20210404002A1 (en) * 2018-10-31 2021-12-30 Yale University Quantitative Algorithm for Endometriosis
WO2020146544A1 (en) * 2019-01-09 2020-07-16 Research Institute At Nationwide Children's Hospital A novel method for monitoring endometriosis and associated disorders
EP3936614A1 (en) 2019-03-07 2022-01-12 Toray Industries, Inc. Kit, device, and method for detecting uterine leiomyosarcoma
ES2787725A1 (en) * 2019-04-15 2020-10-16 Univ Granada METHOD OF OBTAINING USEFUL DATA TO DIAGNOSE HEREDITARY HEMORRHAGIC TELANGIECTASIA (Machine-translation by Google Translate, not legally binding)
CN110144394A (en) * 2019-04-18 2019-08-20 辽宁省肿瘤医院 A kind of Diagnosis of Endometriosis, prognostic marker and its application
BR112022000945A2 (en) * 2019-07-22 2022-03-08 Hoffmann La Roche Methods for assessing whether a patient has endometriosis or is at risk of developing endometriosis, for selecting a patient for therapy, and for monitoring a patient who has endometriosis or is being treated for endometriosis
CN114144674A (en) * 2019-07-22 2022-03-04 豪夫迈·罗氏有限公司 Substance P as a blood biomarker for the non-invasive diagnosis of endometriosis
KR102242639B1 (en) * 2020-01-28 2021-04-21 고려대학교 산학협력단 Biomaker miRNA4668-5p for diagnosing liver fibrosis
KR102316507B1 (en) * 2020-02-28 2021-10-22 차의과학대학교 산학협력단 Biomarker for Ovarian reserve and use thereof
CN111909997B (en) * 2020-09-09 2021-09-28 上海交通大学 Application of miRNA marker in preparation of product for evaluating curative effect of olanzapine on schizophrenia treatment and kit

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317820A1 (en) 2008-05-19 2009-12-24 The Regents Of The University Of California Micro-rna profile in human saliva and its use for detection of oral cancer
EP2730662A1 (en) 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
WO2011109440A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
JP2014513521A (en) * 2011-01-26 2014-06-05 セファイド How to detect lung cancer
US20140024590A1 (en) * 2011-02-18 2014-01-23 Yale University KRAS-Variant And Endometriosis
FR2984358A1 (en) * 2011-12-16 2013-06-21 Genethon METHODS FOR THE DIAGNOSIS OF MUSCLE DYSTROPHIES
WO2013148151A1 (en) 2012-03-29 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Plasma microribonucleic acids as biomarkers for endometriosis and endometriosis-associated ovarian cancer
JP6930832B2 (en) * 2013-11-18 2021-09-01 ディアミール, エルエルシーDiamir, Llc Methods of Using MiRNAs from Body Fluids for the Detection and Monitoring of Parkinson's Disease (PD)
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
US9650676B2 (en) 2014-03-19 2017-05-16 University Of South Carolina Leukocyte MicroRNAS for use in diagnosis and treatment of endometriosis
WO2015148919A2 (en) * 2014-03-27 2015-10-01 Yale University Circulating micrornas as biomarkers for endometriosis
EP2924126B1 (en) * 2014-03-28 2018-04-18 Tervisetehnoloogiate Arenduskeskus AS Method for using microRNA (miRNA) for detection of endometriosis
GB201603967D0 (en) * 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
KR20190057305A (en) 2016-08-30 2019-05-28 예일 유니버시티 MicroRNAs as biomarkers for endometriosis
CA3073829A1 (en) 2017-08-30 2019-03-07 Dot Laboratories, Inc. Methods and compositions for detecting and treating endometriosis
US20210404002A1 (en) 2018-10-31 2021-12-30 Yale University Quantitative Algorithm for Endometriosis
US11315660B2 (en) 2018-10-31 2022-04-26 Dot Laboratories, Inc. Method of detecting and treating endometriosis in a female subject
JP2022530636A (en) 2019-04-29 2022-06-30 イェール ユニバーシティー Classifier for detection of endometriosis

Also Published As

Publication number Publication date
EP3506912B1 (en) 2024-04-03
CA3035429A1 (en) 2018-03-08
US20210180134A1 (en) 2021-06-17
US11220713B2 (en) 2022-01-11
AU2017319325A1 (en) 2019-03-21
US10982282B2 (en) 2021-04-20
US20190276893A1 (en) 2019-09-12
JP2022188086A (en) 2022-12-20
EP3506912A4 (en) 2020-08-19
MX2019002425A (en) 2019-08-16
KR20190057305A (en) 2019-05-28
WO2018044979A1 (en) 2018-03-08
US20220049312A1 (en) 2022-02-17
SG10202102509TA (en) 2021-04-29
EP3506912A1 (en) 2019-07-10
JP2019528081A (en) 2019-10-10
CN109890394A (en) 2019-06-14
BR112019004075A2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201804712PA (en) Biofuel
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201906844RA (en) Biometric feature database establishing method and apparatus
SG11201807038UA (en) Rodents having a humanized tmprss gene
SG11201901172QA (en) A method for manufacturing a fuel component
SG11201811329UA (en) Spheroids including biologically-relevant materials and related methods
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof
SG11201805269QA (en) Process for preparation of polyethylene nanocomposite
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201903602RA (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
SG11201407208UA (en) A method for dynamic generation and modification of an electronic entity architecture
SG11201806568YA (en) Methods, systems, and devices for managing digital tokens, cryptocurrencies, and other distributed ledger-related data
SG11201807478QA (en) Methods and compositions for increased double stranded rna production